Cargando…

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia

OBJECTIVE: This study aimed to examine whether a 12-week small-dose lanthanum carbonate (LaCO3; 500 mg/d) treatment could improve calcium and phosphorus metabolism and parathyroid function in Asian patients with end-stage renal disease (ESRD) under hemodialysis. METHODS: This was a prospective obser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Xiaofei, Jiang, Shuning, Liu, Liang, Tang, Xuejie, Chen, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Makerere Medical School 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652617/ https://www.ncbi.nlm.nih.gov/pubmed/36407374 http://dx.doi.org/10.4314/ahs.v22i2.41

Ejemplares similares

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009)

Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011)

Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
por: Scaria, P. Thomas, et al.
Publicado: (2009)

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020)

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012)

Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
por: Wang, Yong, et al.
Publicado: (2015)

Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis
por: Zhao, Lijuan, et al.
Publicado: (2021)

Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis
por: Chen, Lan, et al.
Publicado: (2018)

Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia
por: Wilson, Rosamund J, et al.
Publicado: (2017)

Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease
por: Zahed, N. S., et al.
Publicado: (2016)

Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
por: GAO, ZHUO, et al.
Publicado: (2013)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis
por: Watanabe, Kentaro, et al.
Publicado: (2020)

Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China
por: Xu, Jing, et al.
Publicado: (2013)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients
por: Nakamura, Kimihiko, et al.
Publicado: (2019)

The Pharmacological Effect and Mechanism of Lanthanum Hydroxide on Vascular Calcification Caused by Chronic Renal Failure Hyperphosphatemia
por: Zhao, Lulu, et al.
Publicado: (2021)

A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis
por: Zhou, Tianbiao, et al.
Publicado: (2018)

Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence
por: Lloret, MªJesús, et al.
Publicado: (2013)

Lanthanum carbonate is not associated with QT interval modification in hemodialysis patients
por: Di Iorio, Biagio, et al.
Publicado: (2010)

Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective
por: Reddy, Yogesh NV, et al.
Publicado: (2014)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea
por: Kim, Gheun-Ho, et al.
Publicado: (2014)

Lanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding
por: Pennick, Michael, et al.
Publicado: (2012)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide
por: Stavroulopoulos, Aristeidis, et al.
Publicado: (2018)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

Correlation Decomposition between TCM Syndrome Types and Calcium and Phosphorus Metabolism in 50 Maintenance Hemodialysis Sufferers
por: Li, Yuanyuan
Publicado: (2022)

Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis
por: MIAO, LI-YING, et al.
Publicado: (2014)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients
por: Hutchison, Alastair J, et al.
Publicado: (2013)

Hyperphosphatemia and risks of acute kidney injury, end-stage renal disease, and mortality in hospitalized patients
por: Moon, Hongran, et al.
Publicado: (2019)

Retracted: Correlation Decomposition between TCM Syndrome Types and Calcium and Phosphorus Metabolism in 50 Maintenance Hemodialysis Sufferers
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease
por: Keith, Michael, et al.
Publicado: (2016)

Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis
por: Moon, Ju-Young, et al.
Publicado: (2015)

Hyperphosphatemia is not significantly associated with increased all-cause mortality in Korean hemodialysis patients
por: Wakasugi, Minako, et al.
Publicado: (2018)

Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
por: Aoki, Yuki, et al.
Publicado: (2022)

Encephalopathy caused by lanthanum carbonate
por: Fraile, Pilar, et al.
Publicado: (2011)

Frequency of Intradialytic Complications in Patients of End-Stage Renal Disease on Maintenance Hemodialysis
por: Ali, Muhammad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_40lhsqt3jr2g2tjlfsu04kjmao